We selected trastuzumab as the targeting antibody due to its routine use as part of the therapeutic arsenal as a single agent or in ADCs formulations to treat HER2-amplified patients.32 Trastuzumab-functionalized NEs effectively recognized their cognate receptors and selectively accumulated into HER2-expressing cancer cell lines (in comparison to HER2-low ones). The gene discussed is ERBB2; the disease is cancer.